A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCICCTG MA. 21: Results of an interim analysis

被引：0
|
作者：
Burnell, M.
Levine, M.
Chapman, J. A.
Bramwell, V
Gelmon, K.
Walley, B.
Whelan, T.
Albain, K.
Perez, E.
Rugo, H.
Ding, Z.
O'Brien, P.
Shepherd, L.
Pritchard, K.
机构：
[1] Atlantic Hlth Sci Corp, St John, NB, Canada
[2] McMaster Univ, Hamilton, ON L8S 4L8, Canada
[3] Queens Univ, NCIC Clin Trials Grp, Kingston, ON K7L 2V7, Canada
[4] Tom Baker Canc Clin, Calgary, AB, Canada
[5] BCCA, Vancouver, BC, Canada
[6] Juravinski Canc Ctr, Hamilton, ON, Canada
[7] SW Oncol Grp, Maywood, IL USA
[8] N Cent Canc Treatment Grp, Jacksonville, FL USA
[9] Canc & Leukemia Grp B, San Francisco, CA USA
[10] Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 103卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：117 / 117
页数：1
相关论文
共 50 条
  • [1] A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: Results of the final relapse free survival analysis.
    Burnell, M. J.
    Shepherd, L.
    Gelmon, K.
    Bramwell, V.
    Walley, B.
    Vandenberg, E.
    Chalchal, H.
    Pritchard, K.
    Whelan, T.
    Albain, K.
    Perez, E.
    Rugo, H.
    O'Brien, P.
    Chapman, J.
    Levine, M.
    [J]. CANCER RESEARCH, 2012, 72
  • [2] Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer
    Burnell, Margot
    Levine, Mark N.
    Chapman, Judith-Anne W.
    Bramwell, Vivien
    Gelmon, Karen
    Walley, Barbara
    Vandenberg, Ted
    Chalchal, Haji
    Albain, Kathy S.
    Perez, Edith A.
    Rugo, Hope
    Pritchard, Kathleen
    O'Brien, Patti
    Shepherd, Lois E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 77 - 82
  • [3] A phase III adjuvant trial of sequenced EC plus filgrastim plus epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA.21)
    Burnell, M. J.
    Levine, M. N.
    Chapman, J. A.
    Bramwell, V.
    Vandenberg, T.
    Chalchal, H. I.
    Albain, K.
    Perez, E.
    Rugo, H.
    Pritchard, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Adriamycin & cyclophosphamide (AC) followed by docetaxel (D) versus AC followed by paclitaxel (P) in operable node positive breast cancer
    Abdel-Halim, I.
    Ei-Sadda, W.
    [J]. BREAST, 2011, 20 : S65 - S65
  • [5] Feasibility of AC/EC Followed by Weekly Paclitaxel in Node-positive Breast Cancer in Japan
    Ishikawa, Takashi
    Shimizu, Satoru
    Katayama, Kiyofumi
    Chishima, Takashi
    Hamaguchi, Yohei
    Doi, Takako
    Tanabe, Mikiko
    Kasahara, Akio
    Yamaguchi, Naotaka
    Narui, Kazutaka
    Ohta, Ikuko
    Matsumoto, Chizuru
    Shimizu, Daisuke
    Kito, Ayako
    Suda, Takashi
    Inaba, Masaaki
    Asaga, Taro
    Momiyama, Nobuyoshi
    Ichikawa, Yasushi
    Yoshimoto, Masataka
    Morita, Satoshi
    Shimada, Hiroshi
    [J]. ANTICANCER RESEARCH, 2009, 29 (05) : 1515 - 1520
  • [6] Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide:: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma
    Fornier, MN
    Seidman, AD
    Theodoulou, M
    Moynahan, ME
    Currie, V
    Moasser, M
    Sklarin, N
    Gilewski, T
    D'Andrea, G
    Salvaggio, R
    Panageas, KS
    Norton, L
    Hudis, C
    [J]. CLINICAL CANCER RESEARCH, 2001, 7 (12) : 3934 - 3941
  • [7] A randomized trial comparing CEF to CME in premenopausal women with node positive breast cancer: update of NCICCTG MA.5.
    Levine, MN
    Pritchard, KI
    Bramwell, VHC
    Shepherd, LE
    Tu, D
    Paul, N
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S33 - S33
  • [8] Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of Paclitaxel in node-positive breast cancer
    Roy, C.
    Choudhury, K. B.
    Pal, M.
    Saha, A.
    Bag, S.
    Banerjee, C.
    [J]. INDIAN JOURNAL OF CANCER, 2012, 49 (03) : 266 - 271
  • [9] A multicenter randomized study comparing the dose dense G-CSF-supported sequential administration of FEC followed by docetaxel versus paclitaxel as adjuvant chemotherapy in women with axillary lymph node positive breast cancer.
    Mavroudis, D.
    Malamos, N.
    Boukovinas, I.
    Kakolyris, S.
    Kourousis, C.
    Athanasiadis, A.
    Ziras, N.
    Makrantonakis, P.
    Polyzos, A.
    Christophylakis, C.
    Georgoulias, V.
    [J]. CANCER RESEARCH, 2012, 72
  • [10] Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer
    Gonzalez-Angulo, A. M.
    Akcakanat, A.
    Liu, S.
    Green, M. C.
    Murray, J. L.
    Chen, H.
    Palla, S. L.
    Koenig, K. B.
    Brewster, A. M.
    Valero, V.
    Ibrahim, N. K.
    Moulder-Thompson, S.
    Litton, J. K.
    Tarco, E.
    Moore, J.
    Flores, P.
    Crawford, D.
    Dryden, M. J.
    Symmans, W. F.
    Sahin, A.
    Giordano, S. H.
    Pusztai, L.
    Do, K-A.
    Mills, G. B.
    Hortobagyi, G. N.
    Meric-Bernstam, F.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (06) : 1122 - 1127
12345